Regeneron Pharmaceuticals Inc said on Tuesday initial data from an ongoing study of its experimental antibody cocktail for use in some hospitalized COVID-19 patients show the therapy was sufficiently effective to warrant continuing the trial. The company is testing the therapy, a combination of two antibodies casirivimab and imdevimab, in hospitalized patients requiring low-flow oxygen. Seronegative patients treated with the antibody cocktail had a lower risk of death or needing mechanical ventilation, the company said. Based on these results, the company said an ongoing late-stage study in hospitalized patients will continue. The U.S. Food and Drug Administration last month issued emergency use authorization for the antibody therapy for use in mild to moderate COVID-19 patients who are not currently hospitalized.

Source: Mint December 30, 2020 02:48 UTC